DBV Technologies (DBVT), a late-stage biopharmaceutical company, is scheduled to present additional data from its positive VITESSE phase 3 study on Feb.28, 2026.
VITESSE is a pivotal phase 3 study assessing the safety and efficacy of VIASKIN Peanut patch for the treatment of peanut-allergic children aged 4 to 7 years. The company reported positive topline results from the study last December.
Peanut allergy is one of the most common food allergies and can cause severe, potentially fatal, allergic reactions, as well as anaphylaxis. The only FDA-approved oral immunotherapy for peanut allergy in children aged 1 to 17 years is PALFORZIA, originally developed by Aimmune Therapeutics and later acquired by Nestlé Health Science. However, its manufacturer, Stallergenes Greer, will stop marketing PALFORZIA, effective July 31, 2026, due to commercial challenges.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.